Stocks Health care IVVD
NASDAQ · Health careInvivyd, Inc. (IVVD)
Invivyd, Inc. brought in $58.4M of revenue over the twelve months to June 30, 2026, up 26.3% from a year earlier. It posted a net loss of $107.3M. In fiscal 2025 capital spending exceeded operating cash flow by $58.3M. At June 30, 2026 it held $160.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Invivyd, Inc.
- Net worth
- Invivyd, Inc. has a market value (market cap) of $169.8M at the latest share price, and shareholders' equity of $181.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $53.4M (+110.5% year on year), with a net loss of $52.5M. Over the 12 months to June 30, 2026: revenue $58.4M, net loss $107.3M.
- Cash flow
- In fiscal 2025 operations used $58.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Invivyd, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Invivyd, Inc. does
Invivyd, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IVVD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $53.4M | -$52.5M | -$0.30 | -$58.3M |
| 2024 | $25.4M | -$169.9M | -$1.43 | -$170.6M |
| 2023 | $0 | -$198.6M | -$1.81 | -$173.8M |
| 2022 | n/a | -$241.3M | -$2.23 | -$221.7M |
| 2021 | n/a | -$226.8M | -$5.32 | -$184.8M |
| 2021 | n/a | -$143.7M | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IVVD ranks in Health care
Latest SEC filings
What Invivyd, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026Other event 8-K
- September 1, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 21% to $14.3M versus the same quarter last year; diluted EPS -$0.14 versus -$0.12.
- August 13, 2026
- July 28, 2026Passive stake (5% or more) SCHEDULE 13G
- July 24, 2026
- July 6, 2026Other event 8-K
- May 19, 2026
Insider trades
What the people running Invivyd, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $177.1K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 18, 2026 | Allen Robert D. IIIChief Scientific Officer | Soldpre-planned (10b5-1) | 17,043 | $14.4K |
| August 18, 2026 | Andersen JillChief Legal Officer, Secretary | Soldpre-planned (10b5-1) | 30,706 | $25.9K |
| August 18, 2026 | Duke William E.Chief Financial Officer | Soldpre-planned (10b5-1) | 18,425 | $15.5K |
| August 18, 2026 | Green JulieChief Human Resources Officer | Soldpre-planned (10b5-1) | 18,425 | $15.5K |
| August 18, 2026 | Lee Timothy EdwardChief Commercial Officer | Soldpre-planned (10b5-1) | 18,425 | $15.5K |
| August 17, 2026 | Allen Robert D. IIIChief Scientific Officer | Soldpre-planned (10b5-1) | 20,679 | $14.9K |
| August 17, 2026 | Andersen JillChief Legal Officer, Secretary | Soldpre-planned (10b5-1) | 37,256 | $26.9K |
| August 17, 2026 | Duke William E.Chief Financial Officer | Soldpre-planned (10b5-1) | 22,355 | $16.1K |
Who owns IVVD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive with 1 related filers | 12.1% | November 14, 2025 |
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | August 14, 2026 |
| Adimab, LLC13D, may seek influence | 7.3% | December 29, 2025 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 7% | May 15, 2026 |
| Maverick Capital, Ltd.13G, passive with 2 related filers | 6.7% | February 13, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 6.3% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 125 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 34,173,104 | new |
| Bvf Inc | 28,165,000 | +8,640,000 |
| Maverick Capital Ltd | 18,970,913 | 0 |
| Perceptive Advisors LLC | 18,490,636 | -2,368,667 |
| BlackRock, Inc. | 16,134,885 | +11,853,095 |
| Vanguard Capital Management LLC | 10,496,507 | +422,181 |
| M28 Capital Management LP | 9,248,250 | 0 |
| Saturn V Capital Management LP | 8,392,288 | -2,556,796 |
| Soleus Capital Management, L.P. | 7,708,727 | 0 |
| Point72 Asset Management, L.P. | 7,542,061 | +7,498,130 |
| Morgan Stanley | 5,730,948 | +2,342,766 |
| Geode Capital Management, LLC | 5,418,774 | +2,949,847 |
| Siren, L.L.C. | 5,000,000 | +1,000,000 |
| Driehaus Capital Management LLC | 4,806,543 | -3,630,351 |
| ADAR1 Capital Management, LLC | 3,807,427 | -15,000 |
| Adage Capital Partners GP, L.L.C. | 3,661,480 | 0 |
| Citadel Advisors LLC | 3,580,941 | +1,991,366 |
| State Street Corp | 3,457,428 | -3,478,220 |
| Qube Research & Technologies Ltd | 3,320,238 | +633,043 |
| Ikarian Capital, LLC | 2,656,570 | 0 |
Insiders
6 insiders reported holding 1,029,350 shares in total, about $592.8K at the last price.
| Holder | Shares |
|---|---|
| Andersen JillChief Legal Officer, Secretary | 283,774 |
| Lee Timothy EdwardChief Commercial Officer | 178,937 |
| Allen Robert D. IIIChief Scientific Officer | 178,765 |
| Duke William E.Chief Financial Officer | 168,937 |
| Green JulieChief Human Resources Officer | 168,937 |
| Mclaughlin Kevin FDirector | 50,000 |
Questions about IVVD
What does Invivyd, Inc. do?
Invivyd, Inc. is a company in the Health care sector, listed on NASDAQ as IVVD. Its shares trade on NASDAQ under the ticker IVVD.
What is Invivyd, Inc.'s net worth?
Invivyd, Inc. has a market value (market cap) of $169.8M at the latest share price, and shareholders' equity of $181.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Invivyd, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $107.3M on revenue of $58.4M.
How much revenue does Invivyd, Inc. make?
Over the twelve months to June 30, 2026 Invivyd, Inc. reported revenue of $58.4M. That is 26.3% more than a year earlier.
When did Invivyd, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 29, 2026.
When is Invivyd, Inc.'s next earnings report?
Invivyd, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare IVVD with
Follow IVVD
Get an email when Invivyd, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Invivyd, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.